Accuray Incorporated (NASDAQ:ARAY) SVP Alaleh Nouri sold 2,166 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.86, for a total value of $10,526.76. Following the transaction, the senior vice president now directly owns 207,068 shares in the company, valued at $1,006,350.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Accuray Incorporated (ARAY) traded up $0.10 during trading on Friday, hitting $5.25. 1,641,858 shares of the stock were exchanged, compared to its average volume of 713,905. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44. Accuray Incorporated has a one year low of $3.60 and a one year high of $6.00.
Accuray (NASDAQ:ARAY) last posted its earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.02. The company had revenue of $91.00 million during the quarter, compared to analyst estimates of $88.26 million. Accuray had a negative net margin of 7.49% and a negative return on equity of 55.18%. Accuray’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.12) earnings per share. sell-side analysts predict that Accuray Incorporated will post -0.18 earnings per share for the current year.
A number of brokerages have recently issued reports on ARAY. Lake Street Capital began coverage on Accuray in a research note on Thursday. They set a “buy” rating and a $10.00 price objective on the stock. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research note on Thursday, August 24th. Cowen reaffirmed a “buy” rating and set a $9.00 price objective on shares of Accuray in a research note on Friday, October 27th. Zacks Investment Research lowered shares of Accuray from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Jefferies Group dropped their target price on shares of Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $6.82.
TRADEMARK VIOLATION NOTICE: “Accuray Incorporated (ARAY) SVP Sells $10,526.76 in Stock” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/01/accuray-incorporated-aray-svp-sells-10526-76-in-stock.html.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.